sözen, hamdullah süleymaniye kadın doğum ve çocuk hastalıkları eğitim ve araştırma hastanesi - kadın hastalıkları ve doğum kliniği, TÜRKİYE , ilhan, gülşah süleymaniye kadın doğum ve çocuk hastalıkları eğitim ve araştırma hastanesi - kadın hastalıkları ve doğum kliniği, turkey , vatansever, doğan lütfi kırdar kartal eğitim ve araştırma hastanesi - kadın hastalıkları ve doğum kliniği, Turkey , demirci, oya zeynep kamil kadın doğum ve çocuk hastalıkları eğitim ve araştırma hastanesi - kadın hastalıkları ve doğum kliniği, Turkey , ertekin, aktuğ zeynep kamil kadın doğum ve çocuk hastalıkları eğitim ve araştırma hastanesi - kadın hastalıkları ve doğum kliniği, TÜRKİYE

EVALUATION OF THE FACTORS DETERMINING THE SUCCESS OF PROSTAGLANDIN E2 TREATMENT FOR CERVICAL RIPENING

26012

Objective: To reveal the factors that may influence the success of prostaglandin E2 treatment applied for cervical ripening when induction of labor was indicated. Materials and methods: Pregnant women with fetal cardiac activity, Bishop score of under 3, cephalic presentation, reactive nonstress test (NST) and without any active contractions were included. Controlled release ovules containing 10 mg dinoprostone were used for cervical ripening. Bishop score of greater than 5 was defined as successful treatment group and lesser than 5 was identified as the group of failed treatment. Age, gravida, parity, vaginal pH, time to the first contraction and time to the active contractions, fetal weight, fetal abdominal circumference (AC) and biparietal diameter (BPD) were compared between the two groups and assessed whether these factors influence the success of the dinoprostone treatment. Results: While maternal age, parity, gestational day calculated on the basis of last menstrual period, fetal BPD, AC measurements were not significant in determining the success (p:0,54; p:0.06; p:0.11; p:0.123; p:0.127); gravida, cervical dilation and effacement, vaginal pH, time to the first contraction and time to the active contractions, fetal weight were significant in determining the success of treatment (p:0.017; p:0.021; p:0.007; p 0.01; p 0.01; p 0.01; p:0.046) Conclusion: Prior to treatment with controlled release ovules containing 10 mg dinoprostone, obstetric history, physical and ultrasonographic examination of patients may predict treatment responses. Patients with higher number of pregnancies, greater cervical dilation, effacement, higher vaginal pH and early appearance of first and effective contractions may increase treatment success.

106

Labor , induction , prostaglandin E2 , dinoporoston , cervix , ripening

Journal Of Istanbul Faculty Of Medicine

112